Precigen Inc stock is traded at $4.73, with a volume of 8,812,246. It is up +5.82% in the last 24 hours and down -39.44% over the past month. Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Previous Close:
$4.47
Open:
$4.48
24h Volume:
8,812,246
Relative Volume:
0.81
Market Cap:
$1.70B
Revenue:
$9.68M
Net Income/Loss:
-$250.64M
P/E Ratio:
-
EPS:
-$1.40
Net Cash Flow:
-$89.83M
1W Performance:
-7.98%
1M Performance:
-39.44%
6M Performance:
+12.35%
1Y Performance:
+21.28%
1-Day Range:
$4.31$4.96
1-Week Range:
$3.92$5.34
52-Week Range:
$3.04$8.98
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen IncSector
HealthcareIndustry
BiotechnologyPhone
301-556-9900Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS